HRP20201225T1 - Terapije poboljšavanja gena kod nasljedne degeneracije mrežnice uzrokovanu mutacijama u genu prpf31 - Google Patents
Terapije poboljšavanja gena kod nasljedne degeneracije mrežnice uzrokovanu mutacijama u genu prpf31 Download PDFInfo
- Publication number
- HRP20201225T1 HRP20201225T1 HRP20201225TT HRP20201225T HRP20201225T1 HR P20201225 T1 HRP20201225 T1 HR P20201225T1 HR P20201225T T HRP20201225T T HR P20201225TT HR P20201225 T HRP20201225 T HR P20201225T HR P20201225 T1 HRP20201225 T1 HR P20201225T1
- Authority
- HR
- Croatia
- Prior art keywords
- vector
- prpf31
- pharmaceutical composition
- eye
- mutations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (13)
1. Vektor Adeno-pridruženog virusa tipa 2 (AAV2) koji sadrži sekvencu koju kodira ljudski PRPF31, operativno povezan s promotorom koji pokreće ekspresiju u epitelnim stanicama retinalnog pigmenta (RPE), pri čemu sekvenca PRPF31 jest ili sadrži ili kodira isti protein kao i nts 1319-2818 od SEQ ID BR.:34.
2. Vektor iz tvrdnje 1, gdje je promotor CAG, CASI, RPE65 ili VMD2 promotor.
3. Vektor iz tvrdnje 1, u kojem je sekvenca PRPF31 optimizirana kodonom.
4. Vektor prema bilo kojoj od prethodnih tvrdnji, koji nadalje sadrži AAV kapsidni polipeptid koji ima aminokiselinsku sekvencu odabranu iz grupe koja se sastoji od SEQ ID BR.: 1, 3, 5, 7, 9, 11, 13, 15, 19, 20, 21, 22, 23, 24, 25 i 26.
5. Farmaceutski sastav koji sadrži vektor iz bilo koje tvrdnje od 1-4, formuliran za primjenu putem sub-retinalne injekcije.
6. Farmaceutski sastav koji se uglavnom sastoji od sustava za isporuku gena koji sadrži vektor bilo koje tvrdnje od 1 do 4 u otapalu.
7. Farmaceutski sastav koji se uglavnom sastoji od sustava za isporuku gena koji sadrži vektor bilo koje tvrdnje od 1 do 4 umetnut u matricu sa sporim otpuštanjem.
8. Farmaceutski sastav prema bilo kojoj od tvrdnji 6 i 7, u kojem sustav za isporuku gena nadalje sadrži pomagačkih virusa, proteina i / ili lipida.
9. Farmaceutski sastav koji sadrži jednu ili više rekombinantnih stanica koje sadrže vektor bilo koje tvrdnje od 1 do 4.
10. Vektor iz tvrdnji 1-4, za upotrebu u liječenju retinitisa pigmentose uzrokovanog mutacijama PRPF31 u oku ljudskog subjekta.
11. Vektor iz tvrdnji 1-4, za upotrebu kod povećanje ekspresije PRPF31 u oku ljudskog subjekta.
12. Farmaceutski sastav prema bilo kojoj od tvrdnji 5 do 9, namijenjen upotrebi u liječenju retinitis pigmentose uzrokovane mutacijama u PRPF31 u oku ljudskog subjekta.
13. Farmaceutski sastav prema bilo kojoj od tvrdnji 5 do 9, za upotrebu kod povećanje ekspresije PRPF31 u oku ljudskog subjekta.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562129638P | 2015-03-06 | 2015-03-06 | |
| US201562147307P | 2015-04-14 | 2015-04-14 | |
| PCT/US2016/021226 WO2016144892A1 (en) | 2015-03-06 | 2016-03-07 | Gene augmentation therapies for inherited retinal degeneration caused by mutations in the prpf31 gene |
| EP16762307.3A EP3265568B1 (en) | 2015-03-06 | 2016-03-07 | Gene augmentation therapies for inherited retinal degeneration caused by mutations in the prpf31 gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201225T1 true HRP20201225T1 (hr) | 2020-11-13 |
Family
ID=56879585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201225TT HRP20201225T1 (hr) | 2015-03-06 | 2016-03-07 | Terapije poboljšavanja gena kod nasljedne degeneracije mrežnice uzrokovanu mutacijama u genu prpf31 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20180043034A1 (hr) |
| EP (2) | EP3748007B1 (hr) |
| JP (3) | JP6812368B2 (hr) |
| CY (1) | CY1123158T1 (hr) |
| DK (1) | DK3265568T3 (hr) |
| ES (1) | ES2806054T3 (hr) |
| HR (1) | HRP20201225T1 (hr) |
| HU (1) | HUE051491T2 (hr) |
| LT (1) | LT3265568T (hr) |
| PL (1) | PL3265568T3 (hr) |
| PT (1) | PT3265568T (hr) |
| RS (1) | RS60668B1 (hr) |
| SI (1) | SI3265568T1 (hr) |
| SM (1) | SMT202000423T1 (hr) |
| WO (1) | WO2016144892A1 (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| CN107012171B (zh) | 2011-04-22 | 2021-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| CN105247044B (zh) | 2013-05-31 | 2021-05-07 | 加利福尼亚大学董事会 | 腺相关病毒变体及其使用方法 |
| EP3800191B1 (en) | 2014-03-17 | 2025-08-20 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| JP7095994B2 (ja) | 2015-03-02 | 2022-07-05 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法 |
| PT3265568T (pt) * | 2015-03-06 | 2020-08-20 | Massachusetts Eye & Ear Infirmary | Terapias de aumento de genes para a degeneração hereditária da retina causada por mutações no gene prpf31 |
| ES2860712T3 (es) * | 2015-03-24 | 2021-10-05 | Univ California | Variantes de virus adenoasociados y métodos de uso de las mismas |
| EP4700118A3 (en) | 2016-07-29 | 2026-04-22 | The Regents of the University of California | Adeno-associated virus virions with varint capsid and methods of use thereof |
| EP3510161A4 (en) | 2016-08-23 | 2020-04-22 | Akouos, Inc. | COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON |
| CA3040179A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
| AU2018265414B2 (en) * | 2017-05-10 | 2022-01-20 | Massachusetts Eye And Ear Infirmary | Methods and compositions for modifying assembly-activating protein (APP)-dependence of viruses |
| EP3645052A4 (en) | 2017-06-30 | 2021-07-28 | Regents of the University of California | ADENO-ASSOCIATED VIRUS VIRIONS WITH ASSOCIATED CAPSIDE VARIANTS AND METHODS OF USE |
| KR20200039617A (ko) | 2017-08-28 | 2020-04-16 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 아데노-연관 바이러스 캡시드 변이체 및 이의 사용 방법 |
| WO2019232517A1 (en) | 2018-06-01 | 2019-12-05 | University Of Florida Research Foundation, Incorporated | Compositions and methods for treatment of dominant retinitis pigmentosa |
| WO2020102740A2 (en) * | 2018-11-16 | 2020-05-22 | Spark Therapeutics, Inc. | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| AU2020241251A1 (en) * | 2019-03-15 | 2021-10-07 | University Of Washington | Improved survival of human cells differentiated in vitro by PRPF31 gene expression knockdown |
| CN116096905A (zh) | 2020-02-21 | 2023-05-09 | 阿库斯股份有限公司 | 用于治疗人受试者的非年龄相关性听力损伤的组合物和方法 |
| CA3174781A1 (en) * | 2020-03-11 | 2021-09-16 | Massachusetts Eye And Ear Infirmary | Gene therapy for nmnat1-associated retinal degeneration |
| EP4356931A4 (en) * | 2021-06-16 | 2025-07-16 | Chigenovo Co Ltd | VARIANT OF PRPF31 AND ITS USE |
| JP2025534556A (ja) * | 2022-10-21 | 2025-10-16 | バイオジェン・エムエイ・インコーポレイテッド | 網膜色素変性症を治療するための組成物及び方法 |
| AU2023390868A1 (en) * | 2022-12-05 | 2025-06-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pigment epithelium-derived factor peptides and use for treating retinal degeneration |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3023787A1 (de) | 1980-06-25 | 1982-01-21 | Studiengesellschaft Kohle mbH, 4330 Mülheim | Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen |
| AU6131086A (en) | 1985-07-05 | 1987-01-30 | Whitehead Institute For Biomedical Research | Epithelial cells expressing foreign genetic material |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| DE3852823T2 (de) | 1987-09-11 | 1995-05-24 | Hughes Howard Med Inst | Transduktionsveränderte fibroblasten und ihre anwendung. |
| JP2914692B2 (ja) | 1987-12-11 | 1999-07-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 内皮細胞の遺伝子修飾 |
| EP0400047B1 (en) | 1988-02-05 | 1997-04-23 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
| EP0452457B1 (en) | 1989-11-03 | 1997-08-20 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| EP0556345B2 (en) | 1990-10-31 | 2005-10-12 | Cell Genesys, Inc. | Retroviral vectors useful for gene therapy |
| ES2150832B1 (es) | 1996-06-12 | 2001-06-16 | Fichtel & Sachs Ag | Dispositivo de maniobra para la maniobra, en particular maniobra neumatica, de un embrague de friccion. |
| US6569662B1 (en) * | 2000-01-21 | 2003-05-27 | Hyseq, Inc. | Nucleic acids and polypeptides |
| WO2002082904A2 (en) * | 2001-04-13 | 2002-10-24 | The Trustees Of The University Of Pennsylvania | Method of treating or retarding the development of blindness |
| US20040208847A1 (en) * | 2003-03-28 | 2004-10-21 | Fabienne Rolling | Method and vectors for selectively transducing retinal pigment epithelium cells |
| WO2007095186A2 (en) * | 2006-02-14 | 2007-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| CA2683469C (en) * | 2007-04-12 | 2019-11-26 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth | Genetic suppression and replacement |
| US20090011040A1 (en) * | 2007-05-02 | 2009-01-08 | Naash Muna I | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
| WO2009134681A2 (en) * | 2008-04-30 | 2009-11-05 | The Trustees Of The University Of Pennsylvania | Aav7 viral vectors for targeted delivery of rpe cells |
| WO2010005533A2 (en) * | 2008-06-30 | 2010-01-14 | The Johns Hopkins University | Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa |
| GB201103062D0 (en) * | 2011-02-22 | 2011-04-06 | Isis Innovation | Method |
| TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| EP2872183B1 (en) * | 2012-07-11 | 2018-09-26 | The Trustees Of The University Of Pennsylvania | Aav-mediated gene therapy for rpgr x-linked retinal degeneration |
| NZ718926A (en) | 2013-10-11 | 2021-12-24 | Massachusetts Eye & Ear Infirmary | Methods of predicting ancestral virus sequences and uses thereof |
| EP3154573A1 (en) * | 2014-06-13 | 2017-04-19 | Universidade De Santiago De Compostela | Nanoparticulate systems for use in gene transfer or gene delivery |
| PT3265568T (pt) | 2015-03-06 | 2020-08-20 | Massachusetts Eye & Ear Infirmary | Terapias de aumento de genes para a degeneração hereditária da retina causada por mutações no gene prpf31 |
-
2016
- 2016-03-07 PT PT167623073T patent/PT3265568T/pt unknown
- 2016-03-07 JP JP2017564778A patent/JP6812368B2/ja active Active
- 2016-03-07 RS RS20200945A patent/RS60668B1/sr unknown
- 2016-03-07 SI SI201630873T patent/SI3265568T1/sl unknown
- 2016-03-07 US US15/555,915 patent/US20180043034A1/en not_active Abandoned
- 2016-03-07 WO PCT/US2016/021226 patent/WO2016144892A1/en not_active Ceased
- 2016-03-07 HU HUE16762307A patent/HUE051491T2/hu unknown
- 2016-03-07 ES ES16762307T patent/ES2806054T3/es active Active
- 2016-03-07 LT LTEP16762307.3T patent/LT3265568T/lt unknown
- 2016-03-07 PL PL16762307T patent/PL3265568T3/pl unknown
- 2016-03-07 DK DK16762307.3T patent/DK3265568T3/da active
- 2016-03-07 EP EP20171646.1A patent/EP3748007B1/en active Active
- 2016-03-07 SM SM20200423T patent/SMT202000423T1/it unknown
- 2016-03-07 EP EP16762307.3A patent/EP3265568B1/en active Active
- 2016-03-07 HR HRP20201225TT patent/HRP20201225T1/hr unknown
-
2020
- 2020-08-04 CY CY20201100718T patent/CY1123158T1/el unknown
- 2020-08-13 US US16/992,689 patent/US20210069347A1/en not_active Abandoned
- 2020-12-16 JP JP2020208068A patent/JP7239550B2/ja active Active
-
2023
- 2023-03-02 JP JP2023031931A patent/JP2023071867A/ja active Pending
-
2024
- 2024-10-25 US US18/927,466 patent/US20250195691A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210069347A1 (en) | 2021-03-11 |
| SMT202000423T1 (it) | 2020-09-10 |
| PL3265568T3 (pl) | 2020-11-30 |
| EP3265568A4 (en) | 2018-08-08 |
| EP3748007C0 (en) | 2024-06-26 |
| US20250195691A1 (en) | 2025-06-19 |
| ES2806054T3 (es) | 2021-02-16 |
| JP6812368B2 (ja) | 2021-01-13 |
| JP2023071867A (ja) | 2023-05-23 |
| JP2021059561A (ja) | 2021-04-15 |
| RS60668B1 (sr) | 2020-09-30 |
| LT3265568T (lt) | 2020-08-25 |
| JP7239550B2 (ja) | 2023-03-14 |
| EP3748007A1 (en) | 2020-12-09 |
| EP3748007B1 (en) | 2024-06-26 |
| DK3265568T3 (da) | 2020-08-10 |
| WO2016144892A1 (en) | 2016-09-15 |
| US20180043034A1 (en) | 2018-02-15 |
| EP3265568A1 (en) | 2018-01-10 |
| CY1123158T1 (el) | 2021-10-29 |
| JP2018511652A (ja) | 2018-04-26 |
| PT3265568T (pt) | 2020-08-20 |
| HK1247637A1 (en) | 2018-09-28 |
| EP3265568B1 (en) | 2020-05-06 |
| HUE051491T2 (hu) | 2021-03-01 |
| SI3265568T1 (sl) | 2020-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211024T4 (hr) | Aav vektori za gensku terapiju mrežnice i cns-a | |
| MX2020005451A (es) | Capsides variantes de virus adenoasociados y uso para inhibir la angiogenesis. | |
| PH12020550094A1 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| PH12018502387A1 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| HRP20251248T1 (hr) | Liječenje amd-a upotrebom varijante aav2 s afliberceptom | |
| JP2017532966A5 (hr) | ||
| HRP20250932T1 (hr) | Dostava mišićno specifičnog mikrodistrofina putem vektora adeno-asociranog virusa za liječenje mišićne distrofije | |
| RU2018114907A (ru) | Композиция и способ для лечения заболевания, опосредованного комплементом | |
| HRP20241577T1 (hr) | Virioni adeno-pridruženog virusa s varijantom kapside i postupci njihove upotrebe | |
| JP2017518271A5 (hr) | ||
| BR112022004027A2 (pt) | Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte | |
| JP2018527941A5 (hr) | ||
| RU2019126509A (ru) | Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе | |
| MX2023012410A (es) | Metodos para tratar enfermedades oculares usando variantes de aav2 que codifican aflibercept. | |
| CN104994882A (zh) | 使用aavsflt-1治疗amd | |
| UY38881A (es) | Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept | |
| JP2017523239A5 (hr) | ||
| IL308645B1 (en) | Viral vectors comprising RDH12 coding regions and methods for treating retinal dystrophies | |
| HK1253299A1 (zh) | 一种通过基因治疗治疗眼疾病的改进方法 | |
| WO2024052734A3 (en) | Respiratory vectors and uses thereof | |
| BR112022003206A2 (pt) | Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte | |
| AR119955A1 (es) | Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept | |
| MY186651A (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| TH2001002705A (th) | เวกเตอร์ของไวรัสซึ่งประกอบรวมด้วยบริเวณในการกำหนดรหัส rdh12 และวิธีการบำบัดโรคจอประสาทตาเสื่อม | |
| NZ731673A (en) | Aav vectors targeted to the central nervous system |